Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2020.0297
PERSPECTIVE
|
Early and underway Precision Medicine trials and novel insights into regulatory networks for colorectal cancer. |
|
|
Abstract
Rapid progress and integration of NGS and CRISPR/Cas9 technologies into early-phase and underway clinical trials highlight the beginning of clinical Cancer Precision Medicine (CPM). Moreover, the breakthrough combination of genome and transcriptome sequencing, editing and mapping including high-G providing now novel knowledge on how coding and non-coding mutation deregulate dynamic transcriptional networks and gene expression. In this Perspective article, basic, translational and clinical integration applying these technologies are discussed with a patient-centric orientation for colorectal cancer.
(Citation: Gastric & Breast Cancer 2020; 15(1): 52-60)
|
|
You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 17 January 2020 |
|